Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)

NCT00389675 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00389675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00389675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2007
Completion date
May 31, 2010
Enrollment
661 (actual)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension